(Q34429041)

2 August 2017

title

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. (English)

1 reference

2 August 2017

0 references

Davidson M

1

1 reference

2 August 2017

McKenney J

2

1 reference

2 August 2017

Stein E

3

1 reference

2 August 2017

Schrott H

4

1 reference

2 August 2017

Bakker-Arkema R

5

1 reference

2 August 2017

Fayyad R

6

1 reference

2 August 2017

Black D

7

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

American Journal of Cardiology

2 August 2017

published in

1 reference

2 August 2017

volume

79

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1475-1481

1 reference

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Studies on reduced and oxidized ubiquinones. I. Simultaneous determination of reduced and oxidized ubiquinones in tissues and mitochondria by high performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900174-4

10.1016/S0002-9149(97)00174-4

7 January 2021

Identifiers

DOI

1 reference

release_almrhmxjcbch5bm45fcrvhgpra

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/almrhmxjcbch5bm45fcrvhgpra

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference